(Q35903574)

11 August 2017

1 reference

title

Immunotherapy for malignant gliomas: emphasis on strategies of active specific immunotherapy using autologous dendritic cells (English)

1 reference

11 August 2017

1 reference

1 reference

Steven De Vleeschouwer

series ordinal

1

1 reference

PubMed ID

15452731

11 August 2017

Stefaan W Van Gool

series ordinal

2

1 reference

PubMed ID

15452731

11 August 2017

Frank Van Calenbergh

series ordinal

3

1 reference

11 August 2017

28 September 2004

1 reference

11 August 2017

Child's Nervous System

1 reference

11 August 2017

21

1 reference

11 August 2017

1

1 reference

11 August 2017

7-18

1 reference

https://scigraph.springernature.com/pub.10.1007/s00381-004-0994-3

11 August 2017

0 references

cites work

Glioma-associated antigen expression in oligodendroglial neoplasms. Tenascin and epidermal growth factor receptor

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00381-004-0994-3

Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00381-004-0994-3

Thymic CD8+ T Cell Production Strongly Influences Tumor Antigen Recognition and Age-Dependent Glioma Mortality

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00381-004-0994-3

Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes.

21 January 2018

1 reference

12 December 2020

Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report

1 reference

12 December 2020

Local application of radiolabeled monoclonal antibodies in the treatment of high grade malignant gliomas: a six-year clinical experience.

1 reference

12 December 2020

Expression of the tumor-rejection antigen SART1 in brain tumors.

1 reference

12 December 2020

Dendritic cells: specialized and regulated antigen processing machines

1 reference

12 December 2020

Survivin in brain tumors: an attractive target for immunotherapy

1 reference

12 December 2020

Glioma immunology and immunotherapy.

1 reference

12 December 2020

Dendritic cells: On the move from bench to bedside

1 reference

12 December 2020

Generation of cytotoxic immune responses against a rat glioma by in vivo priming and secondary in vitro stimulation with tumor cells

1 reference

12 December 2020

A protocol for generation of clinical grade mRNA-transfected monocyte-derived dendritic cells for cancer vaccines.

1 reference

12 December 2020

Immune defects observed in patients with primary malignant brain tumors

1 reference

12 December 2020

Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain

1 reference

12 December 2020

Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens

1 reference

12 December 2020

Tumor antigens in astrocytic gliomas

1 reference

12 December 2020

Activation of the immune system in cancer patients

1 reference

12 December 2020

Birbeck granules (Langerhans' cell granules) in human lymph nodes

1 reference

12 December 2020

Intratumoral LAK cell and interleukin-2 therapy of human gliomas.

1 reference

12 December 2020

Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application

1 reference

12 December 2020

Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms

1 reference

12 December 2020

Dendritic cells pulsed with tumor extract-cationic liposome complex increase the induction of cytotoxic T lymphocytes in mouse brain tumor

1 reference

12 December 2020

In vitro analysis of the proliferative potential of T cells from patients with brain tumor: glioma-associated immunosuppression unrelated to intrinsic cellular defect

1 reference

12 December 2020

T-lymphocyte entry into the central nervous system

1 reference

12 December 2020

Monoclonal antibody analysis of MHC expression in human brain biopsies: tissue ranging from "histologically normal" to that showing different levels of glial tumor involvement.

1 reference

12 December 2020

Pediatric supratentorial high-grade gliomas.

1 reference

12 December 2020

Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor beta 2.

1 reference

12 December 2020

Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells

1 reference

12 December 2020

Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas

1 reference

12 December 2020

Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration

1 reference

12 December 2020

Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors.

1 reference

12 December 2020

Tenascin expression in human glioma cell lines and normal tissues

1 reference

12 December 2020

The brain as an immune privileged site: dendritic cells of the central nervous system inhibit T cell activation.

1 reference

12 December 2020

Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease

1 reference

12 December 2020

7-Hydroxystaurosporine-induced apoptosis in 9L glioma cells provides an effective antigen source for dendritic cells and yields a potent vaccine strategy in an intracranial glioma model

1 reference

12 December 2020

Immunotherapy of malignant brain tumors in children and adults: from theoretical principles to clinical application

1 reference

12 December 2020

Progress in active-specific immunotherapy of brain malignancies

1 reference

12 December 2020

Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma

1 reference

12 December 2020

Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA.

1 reference

12 December 2020

Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo

1 reference

12 December 2020

Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells

1 reference

12 December 2020

Histopathology, classification, and grading of gliomas

1 reference

12 December 2020

Depressed T lymphocyte function in brain tumor patients: Monocytes as suppressor cells

1 reference

12 December 2020

Randomised, controlled study of intratumoral recombinant gamma-interferon treatment in newly diagnosed glioblastoma

1 reference

12 December 2020

Induction of antitumor immunity by intracerebrally implanted rat C6 glioma cells genetically engineered to secrete cytokines

1 reference

12 December 2020

Basic concepts of immunology and neuroimmunology

1 reference

12 December 2020

Time course analysis and modulating effects of established brain tumor on active-specific immunotherapy

1 reference

12 December 2020

Clinical effect of intra-arterial tumor necrosis factor-alpha for malignant glioma.

1 reference

12 December 2020

Comparative analysis of paracrine immunotherapy in experimental brain tumors

1 reference

12 December 2020

The use of dendritic cells in cancer immunotherapy

1 reference

12 December 2020

Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells.

1 reference

12 December 2020

Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs

1 reference

12 December 2020

CD80, CD86 and CD40 provide accessory signals in a multiple-step T-cell activation model.

1 reference

12 December 2020

Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab')2--a preliminary report

1 reference

12 December 2020

Regulation of tumour immunity by CD25+ T cells

1 reference

12 December 2020

Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye.

1 reference

12 December 2020

Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy

1 reference

12 December 2020

Intratumoral injection of dendritic and irradiated glioma cells induces anti-tumor effects in a mouse brain tumor model.

1 reference

12 December 2020

Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha

1 reference

12 December 2020

Identification of a novel cell type in peripheral lymphoid organs of mice. IV. Identification and distribution in mouse spleen

1 reference

12 December 2020

Intravenous recombinant interferon beta in patients with recurrent malignant gliomas: a phase I/II study

1 reference

12 December 2020

Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model.

1 reference

12 December 2020

Polyclonal CTL Responses Observed in Melanoma Patients Vaccinated with Dendritic Cells Pulsed with a MAGE-3.A1 Peptide

1 reference

12 December 2020

Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression.

1 reference

12 December 2020

Tumour escape from the immune response: the last hurdle for successful immunotherapy of cancer?

1 reference

12 December 2020

Intracerebral versus subcutaneous immunization with allogeneic fibroblasts genetically engineered to secrete interleukin-2 in the treatment of central nervous system glioma and melanoma

1 reference

12 December 2020

Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity

1 reference

12 December 2020

Immunotherapy for malignant glioma using human recombinant interleukin-2 and activated autologous lymphocytes. A review of pre-clinical and clinical investigations

1 reference

12 December 2020

Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2.

1 reference

12 December 2020

Dendritic cell development: multiple pathways to nature's adjuvants

1 reference

12 December 2020

Interleukin 10 is expressed in human gliomas in vivo and increases glioma cell proliferation and motility in vitro.

1 reference

12 December 2020

Microglia: Intrinsic immuneffector cell of the brain

1 reference

12 December 2020

Modulation of T-cell function by gliomas

1 reference

12 December 2020

Lymphocyte targeting of the central nervous system: a review of afferent and efferent CNS-immune pathways

1 reference

12 December 2020

Generation of large numbers of dendritic cells in a closed system using Cell Factories.

1 reference

12 December 2020

Presentation of exogenous antigen with class I major histocompatibility complex molecules

1 reference

12 December 2020

A dendritic cell vaccine induces protective immunity to intracranial growth of glioma.

1 reference

12 December 2020

Fibroblasts genetically engineered to secrete cytokines suppress tumor growth and induce antitumor immunity to a murine glioma in vivo

1 reference

12 December 2020

Targeting unique tumor antigens and modulating the cytokine environment may improve immunotherapy for tumors with immune escape mechanisms

1 reference

12 December 2020

The effect of systemic human interferon-alpha administration to patients with glioblastoma multiforme

1 reference

12 December 2020

Cancer statistics, 2000.

1 reference

12 December 2020

Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new view

1 reference

12 December 2020

In vitro generation of human dendritic cells and cell therapy

1 reference

12 December 2020

Transient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy. Case report

1 reference

12 December 2020

Immunobiology of primary intracranial tumors. Part 7: Active immunization of patients with anaplastic human glioma cells: a pilot study.

1 reference

12 December 2020

Cure of established, intracerebral rat gliomas induced by therapeutic immunizations with tumor cells and purified APC or adjuvant IFN-gamma treatment.

1 reference

12 December 2020

Characterization of a spontaneous murine astrocytoma and abrogation of its tumorigenicity by cytokine secretion

1 reference

12 December 2020

Production of prostaglandin E and an interleukin-1 like factor by cultured astrocytes and C6 glioma cells.

1 reference

12 December 2020

Treatment of murine primary brain tumors with systemic interleukin-2 and tumor-infiltrating lymphocytes

1 reference

12 December 2020

Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance

1 reference

12 December 2020

Intratumoral infusion of the monoclonal antibody, mAb 425, against the epidermal-growth-factor receptor in patients with advanced malignant glioma.

1 reference

12 December 2020

Generation of cytotoxic immune responses during the progression of a rat glioma.

1 reference

12 December 2020

Albumin outflow into deep cervical lymph from different regions of rabbit brain.

1 reference

12 December 2020

Assumptions of the tumor 'escape' hypothesis

1 reference

12 December 2020

Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity

1 reference

12 December 2020

Role of interleukin-2 (IL-2) and IL-2 receptor expression in the proliferative defect observed in mitogen-stimulated lymphocytes from patients with gliomas.

1 reference

12 December 2020

Microglial cells in human brain have phenotypic characteristics related to possible function as dendritic antigen presenting cells

1 reference

12 December 2020

Granulocyte-macrophage colony-stimulating factor and B7-2 combination immunogene therapy in an allogeneic Hu-PBL-SCID/beige mouse-human glioblastoma multiforme model.

1 reference

12 December 2020

Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines

1 reference

12 December 2020

Cancer statistics, 1997.

1 reference

12 December 2020

Inflammatory leukocytes associated with increased immunosuppression by glioblastoma

1 reference

12 December 2020

Dendritic cells and the control of immunity

1 reference

12 December 2020

Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2.

1 reference

12 December 2020

Analysis of the role of MHC class II presentation in the stimulation of cytotoxic T lymphocytes by antigens targeted into the exogenous antigen-MHC class I presentation pathway

1 reference

12 December 2020

T cell receptor-mediated signaling is defective in T cells obtained from patients with primary intracranial tumors.

1 reference

12 December 2020

A genetically modified allogeneic cellular vaccine generates MHC class I-restricted cytotoxic responses against tumor-associated antigens and protects against CNS tumors in vivo.

1 reference

12 December 2020

Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial

1 reference

12 December 2020

Failure of cancer vaccines: the significant limitations of this approach to immunotherapy

1 reference

12 December 2020

Immunization with dendritic cells pulsed with tumor extract increases survival of mice bearing intracranial gliomas

1 reference

12 December 2020

Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991.

1 reference

12 December 2020

Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines

1 reference

12 December 2020

Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells

1 reference

12 December 2020

Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients.

1 reference

12 December 2020

Immunotherapy of cancer with dendritic-cell-based vaccines

1 reference

12 December 2020

Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity

1 reference

12 December 2020

Glioblastoma multiforme: a controlled trial to assess the value of specific active immunotherapy in patients treated by radical surgery and radiotherapy

1 reference

12 December 2020

Induction of immunity to tumor-associated antigens following dendritic cell vaccination of cancer patients

1 reference

12 December 2020

Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability

1 reference

12 December 2020

Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma

1 reference

12 December 2020

Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen

1 reference

12 December 2020

Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back

1 reference

12 December 2020

Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy

1 reference

12 December 2020

Immunotherapy of malignancy by in vivo gene transfer into tumors

1 reference

12 December 2020

Molecular pathways in the formation of gliomas.

1 reference

12 December 2020

Transcriptional expression of survivin and its splice variants in brain tumors in humans

1 reference

12 December 2020

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

1 reference

12 December 2020

10.1007/S00381-004-0994-3

Identifiers

DOI

1 reference

11 August 2017

1 reference

PubMed ID

15452731